Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based ...

Choose a SQL Server trial, edition, tool, or connector that best meets your data and workload needs. Get the full-featured free edition, licensed for use as a development and test database in a ...